$1.20
+0.05 (+4.35%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
31 interventional · 9 with posted results
Held by 7 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +2 more) · FINRA short interest 3.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)NCT03491683Percentage of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: INO-5401, INO-9012, Cemiplimab · Radiation: Radiation Therapy · Drug: Temozolomide | Glioblastoma | 52 | 2026-12-31 | in 134 d | 2026-05-04 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaNCT03502785Number of Adverse EventsNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: INO-5401, INO-9012 · Drug: Atezolizumab · Device: CELLECTRA™ 2000 | Urothelial Carcinoma | 35 | 2025-05-09actual | — | 2025-07-10 |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersNCT05430958Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs)Non-randomized · Open-label · Prevention | Phase 1 | Withdrawnsponsor's stated reason: Study was withdrawn due to sponsor decision. | Drug: INO-4800, INO-9112 · Device: CELLECTRA® 2000 | Coronavirus Infection | 0 | Mar 2024 | — | 2022-11-17 |
| Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersNCT04588428results2026-01-22Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEsRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INO-4700, Placebo, INO-4700 · Device: CELLECTRA™ 2000, CELLECTRA™ 2000 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | 192 | 2023-01-19actual | — | 2026-01-22 |
| INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)NCT04398433results2026-04-14Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: INO-3107 · Device: CELLECTRA® 2000 | Respiratory Papillomatosis | 32 | 2022-12-15actual | — | 2026-04-14 |
| Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in GhanaNCT04093076Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Drug: INO-4500, Placebo · Device: CELLECTRA™ 2000 | Lassa Fever | 220 | 2022-10-14actual | — | 2022-11-21 |
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureNCT04642638results2023-12-20Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) AssayRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health. | Drug: INO-4800, Placebo · Device: CELLECTRA® 2000, CELLECTRA® 2000 | Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease | 1,307 | 2022-09-13actual | — | 2023-12-20 |
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03721978results2024-10-17Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical SamplesRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: VGX-3100, Matched Placebo · Device: CELLECTRA™-5PSP | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 203 | 2022-08-23actual | — | 2024-10-17 |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersNCT04336410Percentage of Participants with Adverse Events (AEs)Non-randomized · Open-label · Prevention | Phase 1 | Completed | Drug: INO-4800 · Device: CELLECTRA® 2000 | Coronavirus Infection | 120 | 2022-02-10actual | — | 2022-04-15 |
| Safety, Tolerability and Immunogenicity of INO-4500 in Healthy VolunteersNCT03805984Percentage of Participants with Adverse Events (AEs)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Drug: INO-4500, Placebo · Device: CELLECTRA® 2000 | Lassa Fever | 60 | 2020-10-21actual | — | 2020-11-23 |
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)NCT03180684results2023-08-25Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue SamplesRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: VGX-3100 · Drug: Imiquimod 5% Cream · Device: CELLECTRA™ 2000 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV) | 33 | 2020-07-23actual | — | 2023-08-25 |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03185013results2023-07-25Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical SamplesRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: VGX-3100, Placebo · Device: Electroporation (EP) | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 201 | 2020-07-08actual | — | 2023-07-27 |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2NCT03499795results2023-07-03Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: VGX-3100 · Device: CELLECTRA™ 5PSP | Anal Neoplasm | 23 | 2020-06-16actual | — | 2023-07-14 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseNCT02960594Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03Non-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: INO-1400, INO-9012, INO-1401 | Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma | 93 | 2018-11-09actual | — | 2018-11-19 |
| Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesNCT02241369Adverse events measured and graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: INO-3106, INO-9012 | Aerodigestive Precancerous Lesions and Malignancies | 3 | Sep 2018actual | — | 2018-11-16 |
| Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersNCT02464670Safety Assessment (Composite of multiple measures: adverse events, pain (VAS), lab abnormalities, changes in vital signs)Randomized · Double-masked · Prevention | Phase 1 | Completed | Biological: INO-4201, INO-4202, INO-4201, INO-4212, INO-4212 + INO-9012, INO-4201 + INO-9012 | Ebola Vaccine | 240 | 2018-05-24actual | — | 2019-06-28 |
| Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsNCT02431312Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs)Randomized · Open-label · Treatment | Phase 1 | Completed | Biological: INO-1800, INO-9112 · Drug: Nucleos(t)ide Analogue Treatment | Hepatitis B | 90 | 2018-05-22actual | — | 2019-10-15 |
| Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate CancerNCT02514213Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P · Device: Electroporation using CELLECTRA®-5P | Prostate Cancer | 62 | 2017-12-12actual | — | 2017-12-26 |
| A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerNCT02172911results2021-02-21Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: INO-3112 · Device: CELLECTRA™-5P | Cervical Cancer | 10 | 2017-09-07actual | — | 2021-02-21 |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaNCT02163057results2020-12-23Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: INO-3112 · Device: CELLECTRA™-5P | Head and Neck Squamous Cell Cancer | 22 | 2017-01-23actual | — | 2021-01-22 |
| A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3NCT01304524Number of Participants with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Measure of Efficacy.Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: VGX 3100, Placebo · Device: CELLECTRA™-5P | Cervical Intraepithelial Neoplasia | 167 | May 2014actual | — | 2018-09-07 |
| A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza VirusNCT01405885Safety and tolerability of nine different formulation of multiple combination of H1 and H5 HA plasmid administered ID followed by electroporation in healthy adult subjectsNon-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: INO-3605, INO-3609, INO-3401, INO-3609, INO-3605 AND INO-3609, INO-3510, INO-3609, INO-3609, Seasonal Influenza vaccine, INO-3609 | Healthy | 116 | Aug 2013actual | — | 2014-03-03 |
| Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult ParticipantsNCT01082692Safety and tolerabilityOpen-label · Treatment | Phase 1 | Completed | Biological: PENNVAX-B | HIV-1 Infection, HIV Infections | 12 | Aug 2012actual | — | 2012-11-09 |
| A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001NCT01403155SafetyOpen-label · Prevention | Phase 1 | Completed | Biological: INO-3401 + EP | Healthy | 22 | Aug 2012actual | — | 2017-09-13 |
| Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsNCT01142362Safety and tolerabilityNon-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: VGX-3400X | Healthy | 32 | Nov 2011actual | — | 2017-09-13 |
| Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100NCT01188850Safety and tolerability of a fourth dose of VGX-3100Open-label · Treatment | Phase 1 | Completed | Biological: VGX-3100 | Human Papillomavirus (HPV) | 14 | Oct 2011actual | — | 2018-08-10 |
| Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3NCT00685412Safety and tolerability of escalating doses of VGX-3100, administered by IM injection with EP to adult female subjects post surgical or ablative treatment of grade 2 or 3 CIN.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: VGX-3100 | Papillomavirus Infections | 18 | Jan 2011actual | — | 2017-09-13 |
| Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck CancerNCT00198263To characterize local tumor recurrence through 8 months post-EPT/bleomycin treatmentOpen-label · Treatment | Phase 4 | Completed | Combination product: Medpulser Electroporation with Bleomycin | Head and Neck Cancer | 95 | Sep 2008actual | — | 2017-10-03 |
| Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous CancerNCT00198276Local tumor controlOpen-label · Treatment | Phase 4 | Completed | Combination product: MedPulser Electroporation with bleomycin | Cancer | 88 | Sep 2008actual | — | 2017-10-03 |
| Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell CarcinomaNCT00198315Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35)Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Enrollment was stopped based on the Data Monitoring Committee's recommendation. | Combination product: Medpulser electroporation with Bleomycin · Procedure: Tumor surgical excision | Head and Neck Cancer | 130 | Jun 2007actual | — | 2022-03-04 |
| Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaNCT00198328Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35)Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Enrollment was stopped based on the Data Monitoring Committee's recommendation. | Combination product: Medpulser Electroporation with Bleomycin · Procedure: Surgical Excision | Head Neck Cancer | 84 | Jun 2007actual | — | 2022-03-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19